SCC244 plus osimertinib in patients with stage IIIB/IIIC or IV, EGFR TKI resistant EGFR-mutant NSCLC harboring MET amplification

被引：4
|
作者：
Yu, Y. [1 ]
Yang, N. [2 ]
Zhang, Y. [3 ]
Zhang, H. [4 ]
Li, M. [5 ,16 ]
Yu, Q. [6 ]
Zhou, J. [7 ]
Hu, X. [8 ]
Fang, J. [9 ]
Zhao, H. [10 ]
Feng, J. [11 ]
Li, L. [12 ]
Shu, Y. [13 ]
Wang, X. [14 ]
Sun, M. [15 ]
Zhang, J. [15 ]
Li, M. [5 ,16 ]
Ren, Y. [15 ]
Lu, S. [1 ]
机构：
[1] Shanghai Chest Hosp, Dept Oncol, Shanghai, Peoples R China
[2] Hunan Canc Hosp, Pulm Gastroenterol, Changsha, Peoples R China
[3] Zhejiang Canc Hosp, Med Oncol, Hangzhou, Peoples R China
[4] Guangdong Prov Hosp Chinese Med, Dept Internal Med 1, Guangzhou, Peoples R China
[5] Zhengzhou Univ, Affiliated Hosp 1, Dept Oncol, Zhengzhou, Peoples R China
[6] Guangxi Med Univ, Affiliated Tumor Hosp, Resp Oncol Dept, Nanning, Peoples R China
[7] Zhejiang Univ, Affiliated Hosp 1, Resp Med Dept, Hangzhou, Peoples R China
[8] Henan Tumor Hosp, Med Oncol, Zhengzhou, Peoples R China
[9] Beijing Canc Hosp, Dept Thorac Oncol, Beijing, Peoples R China
[10] Anhui Med Univ, Hosp 2, Dept Pneumol, Hefei, Peoples R China
[11] Nantong Univ, Affiliated Hosp, Dept Resp & Crit Care Med, Nantong, Peoples R China
[12] Sichuan Univ, West China Hosp, Resp Dept, Lung Canc Ctr, Chengdu, Peoples R China
[13] Jiangsu Prov Hosp, Dept Oncol, Nanjing, Peoples R China
[14] Shandong Univ, Qilu Hosp, Dept Chemotherapy, Jinan, Peoples R China
[15] Haihe Biopharma Co Ltd, CSSD, Shanghai, Peoples R China
[16] Haihe Biopharma Co Ltd, BDS, Beijing, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2022年 / 33卷
关键词：
D O I：
10.1016/j.annonc.2022.10.334
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
305MO
引用
收藏
页码：S1553 / S1553
页数：1
相关论文
共 50 条
  • [41] Tepotinib plus osimertinib for EGFR mutant (EGFRm) NSCLC with MET amplification (METamp) after first-line (1L) osimertinib
    Tan, Daniel Shao-Weng
    Kim, Tae Min
    Guarneri, Valentina
    Voon, Pei Jye
    Lim, Boon Khaw
    Wislez, Marie
    Huang, Cheng
    Liam, Chong Kin
    Mazieres, Julien
    Tho, Lye Mun
    Hayashi, Hidetoshi
    Nhung, Nguyen
    Chia, Puey Ling
    De Marinis, Filippo
    Le, Xiuning
    Karachaliou, Niki
    Brutlach, Sabine
    Adrian, Svenja
    Ellers-Lenz, Barbara
    Wu, Yi-Long
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [42] Sintilimab ± IBI305 Plus Chemotherapy for Patients With EGFR-Mutant Non-Squamous NSCLC Failed to EGFR-TKI Treatment
    Lu, S.
    Cheng, Y.
    Wu, L.
    Fang, J.
    Li, B.
    Han, L.
    Zhang, Y.
    Pan, H.
    Wang, Z.
    Sun, Y.
    Ye, F.
    Hu, Y.
    Yu, W.
    Zhou, H.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S649 - S649
  • [43] Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in EGFR-Mutant NSCLC with EGFR Inhibitor Resistance Due to MET Amplification: INSIGHT Final Analysis
    Liam, Chong Kin
    Ahmad, Azura Rozila
    Hsia, Te-Chun
    Zhou, Jianying
    Kim, Dong-Wan
    Soo, Ross Andrew
    Cheng, Ying
    Lu, Shun
    Shin, Sang Won
    Yang, James Chih-Hsin
    Zhang, Yiping
    Zhao, Jun
    Berghoff, Karin
    Bruns, Rolf
    Johne, Andreas
    Wu, Yi-Long
    CLINICAL CANCER RESEARCH, 2023, 29 (10) : 1879 - 1886
  • [44] Phase II two-arm study of tepotinib plus osimertinib in patients with EGFR-mutant NSCLC and acquired resistance to first-line osimertinib due to MET amplification: INSIGHT 2.
    Zhu, Viola Weijia
    Bestvina, Christine M.
    Lopes, Gilberto
    Hamm, John Turner
    Johnson, Melissa Lynne
    Lammers, Philip Edward
    Le, Xiuning
    Marathe, Omkar
    Raez, Luis E.
    Rao, Suman
    Sabari, Joshua K.
    Scheff, Ronald J.
    Tapan, Umit
    Thompson, Jonathan Robert
    Karachaliou, Niki
    Ellers-Lenz, Barbara
    Brutlach, Sabine
    Smit, Egbert F.
    Wu, Yi-Long
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [45] First-Line Continual EGFR-TKI Plus LAT Demonstrated Survival Benefit in Egfr-Mutant Nsclc Patients with Oligoprogressive Disease
    Xu, Q.
    Liu, H.
    Hang, T.
    Ren, S.
    Zhou, C.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S592 - S592
  • [46] A Phase II Study of Fruquintinib in Combination with Gefitinib in Stage IIIb/IV NSCLC Patients Harboring EGFR Activating Mutations
    Lu, S.
    Zhou, J.
    Niu, X.
    Chen, M.
    Hua, Y.
    Su, W.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1735 - S1735
  • [47] The later-line efficacy and safety of immune checkpoint inhibitors plus anlotinib in EGFR-mutant patients with EGFR-TKI-resistant NSCLC: a single-center retrospective study
    Yin, Xiaoyan
    Liu, Xinchao
    Ren, Fei
    Meng, Xiangjiao
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2024, 73 (07)
  • [48] First-line continual EGFR-TKI plus local ablative therapy demonstrated survival benefit in EGFR-mutant NSCLC patients with oligoprogressive disease
    Xu, Qinghua
    Liu, Hui
    Meng, Shuyan
    Jiang, Tao
    Li, Xuefei
    Liang, Shixiong
    Ren, Shengxiang
    Zhou, Caicun
    JOURNAL OF CANCER, 2019, 10 (02): : 522 - 529
  • [49] A Phase Ib Trial of Savolitinib plus Gefitinib for Chinese Patients with EGFR-Mutant MET-Amplified Advanced NSCLC
    Yang, J. -
    Fang, J.
    Shu, Y.
    Chang, J.
    Chen, G.
    He, J.
    Li, W.
    Liu, X.
    Yang, N.
    Zhou, C.
    Huang, J.
    Yang, L.
    Handzel, A.
    Frigault, M.
    Ahmed, G.
    Egile, C.
    Morgan, S.
    Wu, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1769 - S1769
  • [50] The first- or second-line use of pemetrexed sequentially with EGFR-TKI did not differ in PFS for advanced NSCLC patients harboring EGFR-mutant tumors.
    Ding, Zhen-Yu
    Chen, Yue-Yun
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
12345